Literature DB >> 8476574

The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex.

W M Yokoyama1, W E Seaman.   

Abstract

Natural killer cells lyse tumor and virally infected cells in a specific manner that has not been molecularly characterized. Target cell expression of major histocompatibility complex (MHC) class I molecules is correlated with target cell resistance to natural killing. A mechanism to explain this observation is that NK cells may display two types of recognition and activation molecules that have opposing functions when bound to target cell ligands. One type of surface receptor such as the NKR-P1 molecule may activate NK activity whereas the other, represented by the mouse Ly-49 molecule, may engage target cell MHC molecules and inhibit cytotoxicity by transducing "negative" signals. NKR-P1 and Ly-49 are structurally related, and they are encoded by genetically linked loci in a chromosomal region, termed the NK gene complex (NKC), on distal mouse chromosome 6. Target cell susceptibility to natural killing may be dependent upon specific ligand-receptor interaction with these activating or inhibitory NKC-encoded molecules.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8476574     DOI: 10.1146/annurev.iy.11.040193.003145

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  95 in total

1.  H-2Dd engagement of Ly49A leads directly to Ly49A phosphorylation and recruitment of SHP1.

Authors:  M R Daws; M Eriksson; L Oberg; A Ullén; C L Sentman
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

2.  Characterization of a surface membrane molecule expressed by natural killer cells in most inbred mouse strains: monoclonal antibody C9.1 identifies an allelic form of the 2B4 antigen.

Authors:  K Kubota; H Katoh; K Muguruma; K Koyama
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

3.  On the cell biology of pit cells, the liver-specific NK cells.

Authors:  Dian-Zhong Luo; David Vermijlen; Bulent Ahishali; Vasilis Triantis; Georgia Plakoutsi; Filip Braet; Karin Vanderkerken; Eddie Wisse
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

Review 4.  Unravelling natural killer cell function: triggering and inhibitory human NK receptors.

Authors:  Lorenzo Moretta; Alessandro Moretta
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

5.  Ly49Q, a member of the Ly49 family that is selectively expressed on myeloid lineage cells and involved in regulation of cytoskeletal architecture.

Authors:  Noriko Toyama-Sorimachi; Yusuke Tsujimura; Mikako Maruya; Atsuko Onoda; Toshiyuki Kubota; Shigeo Koyasu; Kayo Inaba; Hajime Karasuyama
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-19       Impact factor: 11.205

Review 6.  Regulation of natural killer cell function: a role for the NK cell's own MHC class I molecules.

Authors:  Werner Held; Anick Chalifour; Jérôme D Coudert
Journal:  Med Microbiol Immunol       Date:  2005-01-20       Impact factor: 3.402

7.  A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules.

Authors:  Nadine C Fernandez; Emmanuel Treiner; Russell E Vance; Amanda M Jamieson; Suzanne Lemieux; David H Raulet
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

8.  Altered phenotype and function of natural killer cells expressing the major histocompatibility complex receptor Ly-49 in mice transgenic for its ligand.

Authors:  M Y Olsson; K Kärre; C L Sentman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

Review 9.  Natural killer cell immune responses.

Authors:  Wayne M Yokoyama
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

10.  Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D/p53-/- pancreatic ductal adenocarcinoma.

Authors:  Vanaja Konduri; Dali Li; Matthew M Halpert; Dan Liang; Zhengdong Liang; Yunyu Chen; William E Fisher; Silke Paust; Jonathan M Levitt; Qizhi Cathy Yao; William K Decker
Journal:  Oncoimmunology       Date:  2016-07-22       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.